Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.3K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.3K
Structures of Solids02:22

Structures of Solids

17.9K
Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
17.9K
Metallic Solids02:37

Metallic Solids

20.8K
Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.8K
Network Covalent Solids02:18

Network Covalent Solids

16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Molecular and Ionic Solids02:54

Molecular and Ionic Solids

20.2K
Crystalline solids are divided into four types: molecular, ionic, metallic, and covalent network based on the type of constituent units and their interparticle interactions.
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
20.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026
Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026
Same author

Publisher Correction: Atlas-guided discovery of transcription factors for T cell programming.

Nature·2026
Same author

Atlas-guided discovery of transcription factors for T cell programming.

Nature·2026
Same author

Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.

Open forum infectious diseases·2025
Same author

The landscape of CAR-engineered innate immune cells for cancer immunotherapy.

Nature cancer·2025
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.3K

Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Mekdem Tesfaye1, Barbara Savoldo2

  • 1Division of Pediatric Hematology and Oncology, Duke University Medical Center, Durham, NC, USA.

Current Oncology Reports
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Adoptive cell therapy shows promise for pediatric solid tumors, but challenges like the tumor microenvironment and antigen heterogeneity persist. Ongoing clinical trials are evaluating novel strategies to improve treatment outcomes.

Keywords:
Adoptive cell therapyChimeric antigen receptorImmunotherapyPediatric solid tumorsTransgenic TCR

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

6.1K

Related Experiment Videos

Last Updated: Feb 7, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.3K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

6.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pediatric Cancer Research

Background:

  • Adoptive cell therapy (ACT) faces significant hurdles in treating solid tumors.
  • The tumor microenvironment and variable antigen expression limit ACT efficacy.
  • Pediatric solid tumors present unique challenges for current therapeutic strategies.

Purpose of the Study:

  • To review challenges in applying ACT to solid tumors.
  • To examine novel ACT therapies in development for pediatric solid tumors.

Main Methods:

  • Review of current literature and clinical trial data.
  • Analysis of strategies to overcome ACT limitations in solid tumors.

Main Results:

  • Early trials with GD2 CAR T cells in neuroblastoma show promise but require larger validation.
  • Research for other pediatric solid tumors is largely in preliminary stages.
  • Innovative strategies are emerging to address tumor microenvironment and antigen heterogeneity.

Conclusions:

  • ACT holds potential for improving outcomes in pediatric solid tumors.
  • Further clinical studies are essential to validate promising laboratory findings.
  • Ongoing trials are crucial for advancing ACT in pediatric oncology.